|drug3693||WHO recommendations (waiting condition) Wiki||1.00|
|drug1428||Guided online support program Wiki||1.00|
|D011248||Pregnancy Complications NIH||0.33|
|D003141||Communicable Diseases NIH||0.08|
There is one clinical trial.
This is a multicenter prospective study that aims to investigate the clinical impact of SARS-CoV-2 infection in pregnant women, pregnancy outcomes and perinatal transmission.
Description: Positive Sars-Cov-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samplesMeasure: SARS-CoV-2 Neonatal Infection Time: 7 days
Description: stillbirths and deaths in the first week of lifeMeasure: Perinatal mortality Time: 35 weeks
Description: maternal ICU admission due to COVID-19Measure: ICU maternal admission Time: 35 weeks
Description: Newborn 5 minute Apgar Score < 7Measure: 5 minute Apgar Score < 7 Time: 1 day
Description: Delivery between 24 and 36 weeksMeasure: Preterm labour Time: 35 weeks
Description: Preterm premature rupture of the membranes between 24 and 36 weeksMeasure: PPROM Time: 35 weeks
Description: spontaneous pregnancy loss before 24 weeksMeasure: Miscarriage Time: 14 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports